Medivation, Inc
Biotech Specialty Pharma
55 Hawthorne Street, Suite 610
San Francisco, CA 94105 USA
phone: (415) 543-3470
fax: (415) 543-3411
Symbol MDVN
Exchange NASDAQ
Founded 0
Employees 17
www.medivation.net
Research Sector Biotech Specialty Pharma
Summary Description
Acquires early-development stage medical technologies.
Management
David T. Hung, M.D., President, Chief Executive Officer, Director; C. Patrick Machado, J.D., Senior Vice President, Chief Financial Officer; Lynn Seely, M.D., Chief Medical Officer; Andrew A Protter, Ph.D., Vice President, Preclinical Development; Sue Wollowitz, Ph.D., Vice President, Chemistry and Manufacturing; Lisa Taylor, Vice President, Commercial Development
Ownership
Financials


* numbers in thousands

 
Keywords
acquisition, metastatic Urology, prostate, urinary, bladder, erectile cancer, huntington, alzheimer, j2008

Comment | Printable Version | Jun. 17, 2008
If you work for Medivation, Inc and want to update this profile, click here


Description
Medivation, Inc. is a biopharmaceutical company that acquires promising technologies in the late preclinical development phase and develops them quickly and cost-effectively. WThe current product pipeline consists of small-molecule drugs in clinical development to treat three large, unmet medical needs: Alzheimer's disease, Huntington's disease and hormone-refractory prostate cancer.
Products / Services
Dimebon, a drug shown in a previous pilot clinical trial to appear to improve memory and cognition in patients with Alzheimer's disease, and in preclinical studies to prevent the brain cell death induced by the human gene causing Huntington's disease. The MDV300 Series of compounds, which, based on preclinical data from recent studies, appear to block the growth of metastatic prostate cancer more effectively than a leading current prostate cancer therapy.
Technology / Differentiation
Dimebon, the Companys lead product candidate, is an orally-available, small molecule that has been shown to inhibit brain cell death in preclinical models relevant to Alzheimers disease and Huntingtons disease, making it a potential treatment for these and other neurodegenerative diseases. Based on the clinical and preclinical data generated to date, Medivation believes that Dimebon operates by a novel mechanism of action and may exert a neuroprotective effect in multiple areas of the central nervous system.
Strategy
Medivations current portfolio consists of small molecule drugs in clinical development to treat three large, unmet medical needs  Alzheimers disease, Huntingtons disease and hormone-refractory prostate cancer. The Company intends to build and maintain a portfolio of four to six development programs.


2008-11-22-502